Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Cash & Equivalents: 2010-2024

Historic Cash & Equivalents for China Pharma Holdings (CPHI) over the last 15 years, with Dec 2024 value amounting to $626,879.

  • China Pharma Holdings' Cash & Equivalents fell 58.26% to $300,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $300,000, marking a year-over-year decrease of 58.26%. This contributed to the annual value of $626,879 for FY2024, which is 55.97% down from last year.
  • According to the latest figures from FY2024, China Pharma Holdings' Cash & Equivalents is $626,879, which was down 55.97% from $1.4 million recorded in FY2023.
  • China Pharma Holdings' Cash & Equivalents' 5-year high stood at $4.9 million during FY2021, with a 5-year trough of $626,879 in FY2024.
  • For the 3-year period, China Pharma Holdings' Cash & Equivalents averaged around $1.4 million, with its median value being $1.4 million (2023).
  • In the last 5 years, China Pharma Holdings' Cash & Equivalents spiked by 407.39% in 2021 and then crashed by 58.22% in 2022.
  • Yearly analysis of 5 years shows China Pharma Holdings' Cash & Equivalents stood at $957,653 in 2020, then soared by 407.39% to $4.9 million in 2021, then tumbled by 58.22% to $2.0 million in 2022, then fell by 29.86% to $1.4 million in 2023, then tumbled by 55.97% to $626,879 in 2024.